ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR-NK Therapeutic Strategies.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The clinical outcome predictions of conventional in vitro and in vivo models are often inaccurate because they cannot replicate the tumor microenvironment (TME) complexity. Existing 3D models encounter challenges regarding TME complexity replication, engineering constraints, and limited capacity in analyzing immune-cancer interactions. This study employs 3D embedded bioprinting to develop a heterogeneous lung spheroid (HLS) model, incorporating key stromal factors to better reflect the TME. Transcriptomic profiling via RNA sequencing reveals gene signatures associated with extracellular matrix remodeling, immune suppression, and tumor progression, demonstrating substantial similarity to patient-derived lung tumor samples and validating the biological fidelity of the model. Functional assays demonstrate that the model effectively replicated TME dynamics, as evidenced by reduced CAR-NK cell infiltration, cytotoxicity, and cytokine secretion with increasing model complexity, indicative of a highly immunosuppressive environment. Advanced CAR-NK cells expressing chemokine receptors are utilized to overcome this immune barrier and enhance migration and infiltration within the physiologically relevant lung TME model. Overall, this model replicates critical features of the lung TME, showing potential for evaluating next-generation immunotherapies targeting complex solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.